Post-viral symptoms and conditions are more frequent in COVID-19 than influenza, but not more persistent.

Post-viral symptoms and conditions are more frequent in COVID-19 than influenza, but not more persistent.

Publication date: Oct 09, 2024

Post-viral symptoms have long been known in the medical community but have received more public attention during the COVID-19 pandemic. Many post-viral symptoms were reported as particularly frequent after SARS-CoV-2 infection. However, there is still a lack of evidence regarding the specificity, frequency and persistence of these symptoms in comparison to other viral infectious diseases such as influenza. We investigated a large population-based cohort based on German routine healthcare data. We matched 573,791 individuals with a PCR-test confirmed SARS-CoV-2 infection from the year 2020 to contemporary controls without SARS-CoV-2 infection and controls from the last influenza outbreak in 2018 and followed them up to 18 months. We found that post-viral symptoms as defined for COVID-19 by the WHO as well as tissue damage were more frequent among the COVID-19 cohort than the influenza or contemporary control cohort. The persistence of post-viral symptoms was similar between COVID-19 and influenza. Post-viral symptoms following SARS-CoV-2 infection constitute a substantial disease burden as they are frequent and often persist for many months. As COVID-19 is becoming endemic, the disease must not be trivialized. Research should focus on the development of effective treatments for post-viral symptoms.

Open Access PDF

Concepts Keywords
German Adolescent
Influenza Adult
Matched Aged
Pcr Aged, 80 and over
Claims data
Cohort Studies
Cohort study
COVID-19
Female
Germany
Humans
Influenza
Influenza, Human
Male
Middle Aged
Post-Acute COVID-19 Syndrome
Post-COVID
SARS-CoV-2
SARS-CoV-2
Young Adult

Semantics

Type Source Name
disease MESH COVID-19
disease MESH influenza
pathway REACTOME SARS-CoV-2 Infection
disease MESH infectious diseases
pathway REACTOME Reproduction
disease IDO symptom
disease MESH syndrome
disease MESH chronic fatigue syndrome
disease MESH viral infections
disease MESH infection
drug DRUGBANK Hexocyclium
pathway REACTOME Influenza Infection
disease MESH long COVID
disease MESH death
drug DRUGBANK Ethionamide
drug DRUGBANK Timonacic
drug DRUGBANK Isoxaflutole
disease IDO process
drug DRUGBANK Coenzyme M
disease MESH morbidity
drug DRUGBANK Tretamine
disease MESH dyspnea
disease MESH respiratory insufficiency
disease MESH chest pain
disease MESH cognitive impairment
disease MESH memory disorder
disease MESH pulmonary embolism
disease MESH pericarditis
disease MESH myocarditis
disease MESH melanoma
pathway KEGG Melanoma
disease MESH tinea pedis
disease MESH chronic conditions
drug DRUGBANK Ademetionine
disease MESH dysgeusia
disease MESH anosmia
drug DRUGBANK Trestolone
drug DRUGBANK L-Valine
pathway REACTOME Immune System
disease MESH relapse
disease MESH frailty
disease MESH obesity
disease MESH depression
drug DRUGBANK Oxygen
disease MESH taste disorders
drug DRUGBANK Esomeprazole
drug DRUGBANK Rasagiline
disease IDO site
disease MESH sequelae
disease IDO history
drug DRUGBANK (S)-Des-Me-Ampa
drug DRUGBANK Guanosine
disease MESH Sepsis
disease MESH deep vein thrombosis
disease MESH bleeding

Original Article

(Visited 1 times, 1 visits today)

Leave a Comment

Your email address will not be published. Required fields are marked *